# Medicines and Healthcare Products Regulatory Agency

Report No: UK GMP 36736 Insp GMP 36736/1707035-0003 - NCR

## STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer <sup>1</sup>

### Part 1

Issued following an inspection in accordance with:

Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer: HOSPIRA HEALTHCARE INDIA PRIVATE LIMITED

Site address: PLOT NOS: B3-B4, B5 (PART OF), B6 (PART OF), B11-B18, SIPCOT INDUSTRIAL

PARK, IRUNGATTUKOTTAI, SRIPERUMBUDUR, IN-602 105, India

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-07-01**, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC

Online EudraGMDP, Ref key: 37171 Issuance Date: 2016-08-19 Signatory: Confidential Page 1 of

<sup>&</sup>lt;sup>1</sup> The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

#### Part 2

#### **Human Medicinal Products**

#### 1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

1.1 Sterile products			
1.1.1 Aseptically prepared (processing operations for the following dosage forms)			
1.1.1.2 Lyophilisates			
1.1.1.4 Small volume liquids			
1.1.1.6 Other: Dry Powder aseptic filling(en)			
Other products or manufacturing activity			
1.4.2 Sterilisation of active substance/excipients/finished product			
1.4.2.1 Filtration			
1.6 Quality control testing			
1.6.1 Microbiological: sterility			
1.4.2 Sterilisation of active substance/ excipients/ finished product 1.4.2.1 Filtration  1.6 Quality control testing			

Clarifying remarks (for public users)

The scope of this statement of non-compliance is limited to Sterile medicinal products considered non-critical to public health. National Competent Authorities should evaluate the criticality of products being supplied by this manufacturing site and enact measures to ensure continued supplies where appropriate. Marketing authorisation holders are requested to contact the European Medicines Agency or relevant National Authority to verify whether their products are considered medically critical to public health in their territory and therefore outside the scope of the non-compliance statement Where manufacture and/or testing is continued for critical products, this should be supported by a documented risk assessment containing sufficient information to support activity on a risk management basis.

### Part 3

### 1. Nature of non-compliance:

The inspection identified a critical finding that was in regards to sterility assurance of product. The deficiency covered a number of areas including building classification and segregation by pressure differentials, aseptic processes that had not been optimised to reduce the risk of microbial contamination, aseptic process simulation investigations that failed to identify root cause and take appropriate actions, the environmental monitoring program was not based on a scientific justification and a number of areas of critical risk were not monitored, sterilisation activities including poorly designed autoclave load patterns that presented occluded surfaces and areas that were not free draining, SIP process that had pipework that was not appropriately sloped and also had manual interventions that were not appropriately detailed and all of the above issues were linked to a lack of scientific knowledge.


### Action taken/proposed by the NCA

### **Prohibition of supply**

remains in force. This prohibition does not apply for Solid-dosage products such as tablets and capsules.

### Additional comments


Withdrawal of previous valid GMP Certificate UK GMP 36736 Insp GMP 36736/1707035-0003



Products manufactured at site, if known	Products	Dosage Form	Reference Member State, National or EMA
Human Medicinal Products	PL 04515/0237	IMIPENEM/CILASTATIN 500MG/500MG POWDER FOR SOLUTION FOR INFUSION	MR, UK is RMS
	PL 04515/0371	MEROPENEM 500MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION	MR, UK is RMS
	PL 04515/0372	MEROPENEM 1G POWDER FOR SOLUTION FOR INJECTION OR INFUSION	MR, UK is RMS
	PL 04515/0373	PIPERACILLIN/TAZOBA 2G/0.25G POWDER FOR SOLUTION FOR INJECTION OR INFUSION	MARAMK is RMS
	PL 04515/0374	PIPERACILLIN/TAZOBA 4G/0.5G POWDER FOR SOLUTION FOR INJECTION OR INFUSION	MARAMIK is RMS
	PL 04515/0391	CEFUROXIME 250 MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
	PL 04515/0392	CEFUROXIME 750MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
	PL 04515/0393	CEFUROXIME 1.5G POWDER FOR SOLUTION FOR INJECTION/INFUSION	MR, UK is RMS
	PL 04515/0394	CEFUROXIME 1.5G POWDER FOR SOLUTION FOR INJECTION/INFUSION	MR, UK is RMS
	PL 04515/0397	CEFTRIAXONE 500MG POWDER FOR	MR, UK is RMS

	SOLUTION FOR	
	INJECTION (IM, IV)	
	CEFTRIAXONE 1 G POWDER FOR SOLUTION FOR INJECTION (IM, IV)	MR, UK is RMS
PL 04515/0399	CEFTRIAXONE 2G POWDER FOR SOLUTION FOR INFUSION (IV)	MR, UK is RMS
	CEFTAZIDIME 250 MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
	CEFTAZIDIME 500 MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
	CEFTAZIDIME 1 G POWDER FOR SOLUTION FOR INJECTION/INFUSION	MR, UK is RMS
	CEFTAZIDIME 2 G POWDER FOR SOLUTION FOR INJECTION/INFUSION	MR, UK is RMS
	CEFUROXIME 250MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
	CEFUROXIME 750MG POWDER FOR SOLUTION FOR INJECTION	MR, UK is RMS
CEFUROXIME 1500 MG (1.5G) POWDER FOR SOLUTION FOR INJECTION OR INFUSION	MR, UK is RMS	

PL 30306/0162



Online EudraGMDP, Ref key: 37171 Issuance Date: 2016-08-19 Signatory: Confidential Page 6 of